{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:50:55Z","timestamp":1794307855164,"version":"4.9.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"11","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Autoimmune hemolytic anemia (AIHA) is a rare autoantibody-mediated disease. For steroid and\/or rituximab-refractory AIHA, there is no consensus on optimal treatment. Daratumumab, a monoclonal antibody targeting CD38, could be beneficial by suppression of CD38+ plasma cells and thus autoantibody secretion. In addition, because CD38 is also expressed by activated T cells, daratumumab may also act via immunomodulatory effects. We evaluated the efficacy and safety of daratumumab monotherapy in an international retrospective study including 19 adult patients with heavily pretreated refractory AIHA. In warm AIHA (wAIHA, n\u00a0= 12), overall response was 50% with a median response duration of 5.5\u00a0months (range, 2-12), including ongoing response in 2 patients after 6 and 12\u00a0months. Of 6 nonresponders, 4 had Evans syndrome. In cold AIHA (cAIHA, n\u00a0= 7) overall hemoglobin (Hb) response was 57%, with ongoing response in 3 of 7 patients. One additional patient with nonanemic cAIHA was treated for severe acrocyanosis and reached a clinical acrocyanosis response as well as a Hb increase. Of 6 patients with cAIHA with acrocyanosis, 4 had improved symptoms after daratumumab treatment. In 2 patients with wAIHA treated with daratumumab, in whom we prospectively collected blood samples, we found complete CD38+ T-cell depletion after daratumumab, as well as altered T-cell subset differentiation and a severely diminished capacity for cell activation and proliferation. Reappearance of CD38+ T cells coincided with disease relapse in 1 patient. In conclusion, our data show that daratumumab therapy may be a treatment option for refractory AIHA. The observed immunomodulatory effects that may contribute to the clinical response deserve further exploration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012585","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T16:59:23Z","timestamp":1710953963000},"page":"2622-2634","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease"],"prefix":"10.1182","volume":"8","author":[{"given":"Marit","family":"Jalink","sequence":"first","affiliation":[{"name":"1Center for Clinical Transfusion Research, Sanquin Research, Amsterdam, The Netherlands"},{"name":"2Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaja F.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"3Experimental Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands"},{"name":"4Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands"},{"name":"5Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, The Netherlands"},{"name":"6Cancer Center Amsterdam, Cancer Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4993-7828","authenticated-orcid":false,"given":"Jahanzaib","family":"Khwaja","sequence":"additional","affiliation":[{"name":"7University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-4682","authenticated-orcid":false,"given":"Dorothea","family":"Evers","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coty","family":"Bruggeman","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Martini Ziekenhuis, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-8379","authenticated-orcid":false,"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[{"name":"10Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy"},{"name":"11Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Michel","sequence":"additional","affiliation":[{"name":"12Centre de R\u00e9f\u00e9rence des Cytop\u00e9nies Auto-Immunes de l'Adulte, Service de M\u00e9decine Interne, CHU Henri Mondor, AP-HP, Universit\u00e9 Paris-Est Cr\u00e9teil, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3964-4968","authenticated-orcid":false,"given":"Etienne","family":"Crickx","sequence":"additional","affiliation":[{"name":"12Centre de R\u00e9f\u00e9rence des Cytop\u00e9nies Auto-Immunes de l'Adulte, Service de M\u00e9decine Interne, CHU Henri Mondor, AP-HP, Universit\u00e9 Paris-Est Cr\u00e9teil, Cr\u00e9teil, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0627-4358","authenticated-orcid":false,"given":"Quentin A.","family":"Hill","sequence":"additional","affiliation":[{"name":"13Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-1062","authenticated-orcid":false,"given":"Ulrich","family":"Jaeger","sequence":"additional","affiliation":[{"name":"14Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3190-1891","authenticated-orcid":false,"given":"Arnon P.","family":"Kater","sequence":"additional","affiliation":[{"name":"3Experimental Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands"},{"name":"4Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands"},{"name":"5Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, The Netherlands"},{"name":"6Cancer Center Amsterdam, Cancer Immunology, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0450-0833","authenticated-orcid":false,"given":"Anja B. U.","family":"M\u00e4kelburg","sequence":"additional","affiliation":[{"name":"15Department of Hematology, University Medical Center Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Breedijk","sequence":"additional","affiliation":[{"name":"16Department of Internal Medicine, Deventer Ziekenhuis, Deventer, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A. W.","family":"te Boekhorst","sequence":"additional","affiliation":[{"name":"17Department of Hematology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3136-3739","authenticated-orcid":false,"given":"Marlijn P. A.","family":"Hoeks","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masja","family":"de Haas","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"18Department of Immunohematology Diagnostics, Sanquin, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"D\u2019Sa","sequence":"additional","affiliation":[{"name":"7University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3229-9556","authenticated-orcid":false,"given":"Josephine M. I.","family":"Vos","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Amsterdam University Medical Center, Amsterdam, The Netherlands"},{"name":"5Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, The Netherlands"},{"name":"18Department of Immunohematology Diagnostics, Sanquin, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,5,29]]},"reference":[{"key":"2024061016060661600_bib1","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting","volume":"41","author":"Jager","year":"2020","journal-title":"Blood Rev"},{"issue":"4","key":"2024061016060661600_bib2","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood.2020005674","article-title":"Cold agglutinin disease revisited: a multinational, observational study of 232 patients","volume":"136","author":"Berentsen","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2024061016060661600_bib3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/hemato3040040","article-title":"Cold agglutinin disease: improved understanding of pathogenesis helps define targets for therapy","volume":"3","author":"Berentsen","year":"2022","journal-title":"Hemato"},{"issue":"4","key":"2024061016060661600_bib4","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86 patients","volume":"91","author":"Berentsen","year":"2006","journal-title":"Haematologica"},{"issue":"15","key":"2024061016060661600_bib5","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2217\/imt-2022-0085","article-title":"Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?","volume":"14","author":"Berentsen","year":"2022","journal-title":"Immunotherapy"},{"issue":"7","key":"2024061016060661600_bib6","doi-asserted-by":"crossref","first-page":"e34248","DOI":"10.2196\/34248","article-title":"The burden of cold agglutinin disease on patients' daily life: web-based cross-sectional survey of 50 American patients","volume":"6","author":"Joly","year":"2022","journal-title":"JMIR Form Res"},{"key":"2024061016060661600_bib7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaut.2015.05.006","article-title":"Emergence of long-lived autoreactive plasma cells in the spleen of primary warm auto-immune hemolytic anemia patients treated with rituximab","volume":"62","author":"Mahevas","year":"2015","journal-title":"J\u00a0Autoimmun"},{"issue":"14","key":"2024061016060661600_bib8","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMoa2027760","article-title":"Sutimlimab in cold agglutinin disease","volume":"384","author":"Roth","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024061016060661600_bib9","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2024061016060661600_bib10","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomized, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024061016060661600_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"key":"2024061016060661600_bib12","doi-asserted-by":"crossref","first-page":"649441","DOI":"10.3389\/fimmu.2021.649441","article-title":"The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease","volume":"12","author":"Zaninoni","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"2024061016060661600_bib13","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.3324\/haematol.2021.279232","article-title":"Daratumumab, an original approach for treating multi-refractory autoimmune cytopenia","volume":"106","author":"Crickx","year":"2021","journal-title":"Haematologica"},{"issue":"3","key":"2024061016060661600_bib14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2024061016060661600_bib15","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.3324\/haematol.2021.279487","article-title":"Daratumumab: new indications revolving around \"off-targets\"","volume":"106","author":"Ofran","year":"2021","journal-title":"Haematologica"},{"issue":"5","key":"2024061016060661600_bib16","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1111\/bjh.17565","article-title":"Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series","volume":"194","author":"Khandelwal","year":"2021","journal-title":"Br J Haematol"},{"issue":"5","key":"2024061016060661600_bib17","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/bjh.17655","article-title":"Daratumumab in rituximab-refractory autoimmune hemolytic anemia","volume":"194","author":"Rieger","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2024061016060661600_bib18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40348-021-00114-y","article-title":"Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature","volume":"8","author":"Driouk","year":"2021","journal-title":"Mol Cell Pediatr"},{"issue":"5","key":"2024061016060661600_bib19","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s00277-020-04063-w","article-title":"Daratumumab for refractory warm autoimmune hemolytic anemia","volume":"100","author":"Jain","year":"2021","journal-title":"Ann Hematol"},{"issue":"10","key":"2024061016060661600_bib20","doi-asserted-by":"crossref","first-page":"E263","DOI":"10.1002\/ajh.27025","article-title":"Bortezomib and daratumumab in refractory autoimmune hemolytic anemia","volume":"98","author":"McGlothlin","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"2024061016060661600_bib21","doi-asserted-by":"crossref","first-page":"2252651","DOI":"10.1080\/16078454.2023.2252651","article-title":"Refractory cold agglutinin disease successfully treated with daratumumab. a case report and review of literature","volume":"28","author":"Mohamed","year":"2023","journal-title":"Hematology"},{"issue":"10","key":"2024061016060661600_bib22","doi-asserted-by":"crossref","first-page":"E293","DOI":"10.1002\/ajh.25932","article-title":"Daratumumab for disabling cold agglutinin disease refractory to B-cell directed therapy","volume":"95","author":"Tomkins","year":"2020","journal-title":"Am J Hematol"},{"issue":"12","key":"2024061016060661600_bib23","first-page":"3859","article-title":"New insights in autoimmune hemolytic anemia: from pathogenesis to therapy stage 1","volume":"9","author":"Barcellini","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"2024061016060661600_bib24","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-12-4692","article-title":"CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia","volume":"105","author":"Mqadmi","year":"2005","journal-title":"Blood"},{"issue":"4","key":"2024061016060661600_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/0891693031000151238","article-title":"Mechanisms of immunological tolerance loss versus erythrocyte self-antigens and autoimmune hemolytic anemia","volume":"36","author":"Fagiolo","year":"2003","journal-title":"Autoimmunity"},{"issue":"3","key":"2024061016060661600_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/08916934.2016.1138219","article-title":"Expansion of CD8+ cells in autoimmune hemolytic anemia","volume":"49","author":"Smirnova","year":"2016","journal-title":"Autoimmunity"},{"issue":"24","key":"2024061016060661600_bib27","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1182\/bloodadvances.2021005610","article-title":"Evans syndrome in adults: an observational multicenter study","volume":"5","author":"Fattizzo","year":"2021","journal-title":"Blood Adv"},{"issue":"20","key":"2024061016060661600_bib28","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.2021012039","article-title":"Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease\/cold agglutinin syndrome","volume":"138","author":"Jalink","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2024061016060661600_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/0976-500X.85930","article-title":"Belimumab: first targeted biological treatment for systemic lupus erythematosus","volume":"2","author":"Dubey","year":"2011","journal-title":"J\u00a0Pharmacol Pharmacother"},{"issue":"2","key":"2024061016060661600_bib30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/cyto.a.24518","article-title":"Comprehensive phenotyping of human peripheral blood B lymphocytes in pathological conditions","volume":"101","author":"Carsetti","year":"2022","journal-title":"Cytometry A"},{"issue":"7","key":"2024061016060661600_bib31","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A"},{"key":"2024061016060661600_bib32","doi-asserted-by":"crossref","first-page":"1228142","DOI":"10.3389\/fimmu.2023.1228142","article-title":"Severe autoimmune hemolytic anemia; epidemiology, clinical management, outcomes and knowledge gaps","volume":"14","author":"Mulder","year":"2023","journal-title":"Front Immunol"},{"key":"2024061016060661600_bib33","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3389\/fimmu.2020.00590","article-title":"New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia","volume":"11","author":"Berentsen","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"2024061016060661600_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.pathol.2017.02.004","article-title":"Role of plasma cells in Waldenstrom macroglobulinemia","volume":"49","author":"El-Ayoubi","year":"2017","journal-title":"Pathology"},{"issue":"9","key":"2024061016060661600_bib35","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood.2021014955","article-title":"Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial","volume":"140","author":"Roth","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2024061016060661600_bib36","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"2024061016060661600_bib37","doi-asserted-by":"crossref","first-page":"113395","DOI":"10.1016\/j.biopha.2022.113395","article-title":"CD38: an important regulator of T cell function","volume":"153","author":"Li","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2024061016060661600_bib38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1189\/jlb.0404262","article-title":"CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines","volume":"77","author":"Sandoval-Montes","year":"2005","journal-title":"J\u00a0Leukoc Biol"},{"issue":"12","key":"2024061016060661600_bib39","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N\u00a0Engl J Med"}],"updated-by":[{"DOI":"10.1182\/bloodadvances.2024015206","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000}}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2622\/2228579\/blooda_adv-2024-012585-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2622\/2228579\/blooda_adv-2024-012585-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T12:08:01Z","timestamp":1718021281000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/11\/2622\/515376\/Daratumumab-monotherapy-in-refractory-warm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012585","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,29]]}}}